65,437 trials
Subcortical Aphasia · Ischemic Stroke
Primary: A Change of Outcome Measure:the Chinese Version of Western Aphasia Battery(WAB) — 78.16; 78.60; 88.24; 83.51 score on a scale
Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN
Primary: Overall Survival (OS) — 6.5; 7.6; 8.3 Months — p=0.7624
Precapillary Pulmonary Hypertension
Primary: Changes in Right Ventricular Ejection Fraction (RVEF %) After 3 Months Intervention — -2.8; 3.9 percentage of ejected blood — p=0.008
Visual Acuity, Slit Lamp Biomicroscopy (Corneal Staining Assessment)
Primary: Subject Comfort — 92.4; 92.4; 92.0; 63.0 Units on a scale
Muscular Atrophy, Spinal
Primary: Safety: Frequency of Adverse Events/Lab Abnormalities
Human Immunodeficiency Virus (HIV) Infection
Primary: Number of Participants With an Adverse Event (AE) — 0 Participants
Breast Cancer
Primary: Disease-free Survival After Prolonged Endocrine Treatment — NA; NA Years — p=0.425
Carcinoid Tumors · Pancreatic NET
Primary: Overall Radiographic Response Rate (ORR) — 0 Participants
Seborrheic Keratosis
Primary: Subject Satisfaction — 21; 14; 4; 0 Participants
Diabetes Mellitus, Type 2
Primary: Percentage of Participants With Drug Related Adverse Events — 11.39 Percentage (%) of participants
Heart Arrest · Sport Injury · Inflammatory Response
Primary: Cardiac Troponin I (cTnI) — 6.6; 10.1; 25.0 ng/dL
Schizophrenia · Schizoaffective Disorder · Type 2 Diabetes Mellitus
Primary: DEXA Total Fat — 32.24; 27.66; 28.83; 31.60 kilograms of body fat — p=0.002
Mental Health
Primary: Emergency Department to Inpatient Conversion Rate — 178; 198 participants — p=0.06
Diabetic Neuropathy
Primary: Sural Nerve Amplitude — 1.22; 2.37; 0.88; 0.86 uV — p=0.49
Muscular Atrophy, Spinal
Primary: Efficacy: Functional Motor Testing, Including Gross Motor Function Measure (GMFM) and Timed Motor Tests